Navigation Links
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Date:5/10/2013

ctions into the brain of NSI-566. The INDs for both acute spinal cord injury Phase I/II in Seoul and ALS Phase I/II in Mexico City are expected to be filed in June.

"Additionally, we were approved by the FDA to treat the third and final cohort of the ongoing Phase Ib major depressive disorder trial with our lead neurogenic small molecule compound, NSI-189. Dosing is proceeding well, and we expect to complete the trial in September," Dr. Johe concluded.

"This past quarter we were pleased to grant licenses for our proprietary intraspinal cell therapy surgical devices and method, used in the Phase I NSI-566/ALS trial, to Cedars-Sinai Medical Center. The licenses are specifically for academic research, enabling a new era of research and treatment of spinal cord conditions and diseases," stated Richard Garr , Neuralstem President and CEO. "Additionally, we further strengthened our substantial global IP portfolio to include five licensed patent grants in Europe for the floating cannula and cell therapy method of use. Our newest U.S. patent covers the use of expanded spinal cord stem cells to treat ALS and joins past patent claims covering methods of culturing and treating neurodegenerative conditions with our NSI-566 cells. In our neurogenic small molecule program, we received one U.S. patent covering divisional compositions and methods of use, and 11 European patents for method of discovering neurogenic agents.

"Finally, Dr. Johe and I would like to thank our  scientific and medical collaborators, and the patients and their families in the ALS community who believe in the science, technology and promise of Neuralstem for appearing at the recent FDA hearing on ALS trials and being vocal with their support," added Garr. 

First Quarter Clinical Program and Business Highlights In January, Neuralstem's lead cell therapy candidate,
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
7. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
8. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... HCTL ), today announced unaudited results for the,second quarter ... for the first six months of 2007 were $7.75 million, ... The gross profit for the,first half of the year was ... The net loss for such period was $(319) thousand, versus ...
... 16 Cepheid (Nasdaq:,CPHD) today announced that it ... Northrop Grumman for the purchase of up to ... associated materials. The,anthrax test is currently used in ... Service (USPS) mail processing centers,nationwide. The agreement covers ...
... Topic of Drug Repurposing and ... Indian Clinical Trial Strategy, ... biopharmaceutical company, announced today,that Chief Executive Officer, John Maki, and ... 234th American Chemical,Society National Meeting on Sunday, August 19, 2007. ...
Cached Biology Technology:Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 2Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 3Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 2Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:4/23/2014)... found evidence of an interaction between prenatal smoking ... in children, especially in girls. , "The interesting ... prenatal smoking will have behavioral problems. Some ... Assistant Professor at Sam Houston State University, College ... study. "One possible explanation for this is ...
(Date:4/23/2014)... yesterday, Argentina joins the European Molecular Biology Laboratory ... strengthens the ties between the European and Latin ... access to EMBL,s world-class facilities and programs, and ... inception, fostering excellent life science research and promoting ... EMBL,s mission," says EMBL Director General Iain Mattaj ...
(Date:4/23/2014)... coined term for novels and films which focus on the ... shows how these fictions serve as a mental laboratory that ... and imagine other living conditions. , "Global warming is ... it is also a cultural phenomenon in which meaning is ... we see. And there are so many of them now ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... Life Sciences Discovery Fund (LSDF) today announced its ... will receive life sciences program grants totaling more ... will focus on advancing vaccine development, improving the ... of mental health and substance abuse services in ...
... all a protein needs to do is give quick squeezes ... from The University of Arizona in Tucson. Scientists ... readings of the information coded in the DNA,s sequence. ... called direct readout, can effectively pinpoint sites on DNA using ...
... . , Montreal, December 16, 2008 ... Stephen Michnick is helping the scientific community uncover the ... biochemistry professor and Canada Research Chair in Integrative Genomics, ... him to examine how proteins interact within cells. ...
Cached Biology News:Life Sciences Discovery Fund awards health research program grants 2Life Sciences Discovery Fund awards health research program grants 3Life Sciences Discovery Fund awards health research program grants 4Life Sciences Discovery Fund awards health research program grants 5Just a little squeeze lets proteins assess DNA 2Just a little squeeze lets proteins assess DNA 3Call Stephen Michnick a gene grammarian 2
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Biology Products: